Prostate Cancer Clinical Trial
Official title:
A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy
Verified date | February 2015 |
Source | Dendreon |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The main purpose of this study is to determine whether ADT started before or after sipuleucel-T leads to a better immune system response. This study will also evaluate the safety of sipuleucel-T treatment, immune system responses over time, the characteristics of sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.
Status | Completed |
Enrollment | 68 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically documented prostate cancer - Prior primary therapy for prostate cancer - Rising prostate specific antigen (PSA) with a PSA doubling time (PSADT) of = 12 months - Non-metastatic disease with ECOG performance status = 1 - Testosterone = 200 ng/dL = 28 days of registration - Adequate hematologic, renal, and liver function - Must live in a permanent residence within a comfortable driving distance (roundtrip within one day) to the clinical research site Exclusion Criteria: - Requires systemic ongoing immunosuppressive therapy - History of allergic reactions attributed to compounds of similar chemical or biologic composition to sipuleucel-T or GM-CSF - Prior sipuleucel-T therapy - Prior ADT therapy = 6 months prior to registration or more than 6 months duration in total - Disease-free and off treatment for 10 years for other stage III/IV malignancies or 5 years for other stage I/II malignancies - Prior experimental immunotherapy within 1 year - Received denosumab or XRT = 6 months prior to registration - Received chemotherapy or GM-CSF = 90 days prior to registration - Received any of the following medications or interventions = 28 days prior to registration - major surgery requiring general anesthesia - systemic immunosuppressive therapy - other prescription treatment for prostate cancer - Active infection within 1 week of registration - Likely to receive XRT or surgery for prostate cancer during the study period |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Community Care Physicians, PC | Albany | New York |
United States | NYOH Albany Cancer Center at Patroon Creek | Albany | New York |
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
United States | The Urology Center of Colorado | Denver | Colorado |
United States | Urology Center of Alabama | Homewood | Alabama |
United States | University of California San Diego / Moores Cancer Center | La Jolla | California |
United States | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada |
United States | Keck Hospital of USC | Los Angeles | California |
United States | LAC + USC Medical Center | Los Angeles | California |
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Grand Strand Urology | Myrtle Beach | South Carolina |
United States | Urology San Antonio Research | San Antonio | Texas |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
United States | Virginia Mason Medical Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Dendreon |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure change in immune response to PA2024 by IFN-gamma production ELISPOT following sipuleucel-T/ADT treatment regimens. | To determine whether ADT started before or after sipuleucel-T leads to superior augmentation of immune response to sipuleucel-T. | Change in immune response from baseline through Month 24 | No |
Secondary | Number of Participants with Adverse Events as a Measure of Safety | From baseline up to 3 years | Yes | |
Secondary | Measure changes in immune responses over time | Immune responses will be assessed from baseline through Month 24 by IFN-gamma ELISPOT assay, T cell proliferation assay, and production of antibodies (humoral response) to PAP and/or PA2024. | From baseline through Month 24 | No |
Secondary | Measure changes in sipuleucel-T product parameters: CD54 upregulation, number of CD54+ cells, and total nucleated cell number | A course of sipuleucel-T therapy consists of 3 complete doses given at approximately 2-week intervals. | Over the course of sipuleucel-T therapy (approximately 1 month) | No |
Secondary | Measure changes in PSA over time | From baseline through Month 27 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |